NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/22/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization25.23 mln
Float7.86 mln
Earnings Date06/13/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
24
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-161
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
BriaCell Therapeutics Corp. is a Canadian cancer treatment company working to develop new ways to use the immune system to fight tumors, with a particular focus on advanced breast cancer. Its main treatment, Bria-IMT, is currently being tested in Phase 3 clinical trials, while a related therapy called Bria-OTS is being developed as a ready-made, personalized option for patients with several types of cancer, including prostate cancer. The company also holds a licensing agreement with the University of Maryland Baltimore County to advance a protein-based therapy that helps the immune system recognize and attack cancer cells. BriaCell works with the MSK Accelerator to speed up the development of its treatments across a range of cancer types.
